Eisai CEO Haruo Naito Appointed Knight Commander of British Empire
October 31, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Eisai CEO Haruo Naito Appointed Knight Commander of British Empire - JCN Newswire
Share:
Eisai CEO Haruo Naito Appointed Knight Commander of British Empire

Tokyo, Apr 15, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that in recognition of his valuable contribution to relations between Britain and Japan, Her Majesty Queen Elizabeth II has appointed Dr. Haruo Naito, President & CEO of Eisai Co., Ltd. to be an Honorary Knight Commander of the Order of the British Empire (KBE).

The Honorary Knight Commander of the Order of the British Empire (KBE) award recognizes excellent achievement in a wide variety of fields and appreciates contributions to greater society, and is especially awarded to people who have left behind significant accomplishments, or people who have dedicated themselves to social services.

Statement from the British Embassy

Dr. Naito has continued to demonstrate steadfast commitment to the U.K. and Europe, acting as de facto figurehead for the British Government's campaign to attract investment from the Japanese life sciences industry. The most striking evidence of his championing of the U.K. is the GBP100 million investment in 2009
to build the European Knowledge Centre in Hatfield as Eisai's strategic base in Europe. Since then the company has further extended the British base to support its growing European, African and Middle Eastern business, and opened a new solid dose global manufacturing line for the anti-epileptic agent Fycompa in Hatfield in 2012. The company also continues to conduct ground-breaking research and
development in the U.K., including via its long-standing collaboration with University College London, with whom the company has an alliance to develop therapeutics for neurological disease.

Comment from Dr. Naito

It is a great honor to be appointed Honorary Knight Commander of the Order of the British Empire (KBE). Since Eisai established its first European office in London in 1988, we have built a strong relationship with the U.K. throughout the course of a quarter of a century. In 1990, Eisai established the Eisai London Research Laboratories at the University College London in the U.K., and has made many accomplishments through the exchange of knowledge and experience between leading scientists from the U.K. and Japan. In 2009, Eisai established the European Knowledge Centre, which integrates the company's European headquarters, research & development, production and marketing functions into one site, in Hatfield. Currently, it looks beyond Europe to the Middle East, Africa and Australia as well, and forms one of our primary global business units. Together with strengthening the positive mutual trust we have cultivated between Japan and the U.K. until now, we intend to take this honor as a further impetus to
realize the creation of innovative new medicines based on Britain's world-leading life science infrastructure, and make an even greater contribution to global health and welfare.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


 


Apr 15, 2014
Source: Eisai

Eisai (TSE: 4523) (U.S: ESALY)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Executive appointment
View more news from these Sectors: CSR, Drugs & OTC, Biotech


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)